Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002094 · ClinicalTrials.gov registry record · NA
Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E
A NA study, sponsored by Pharmacia and Upjohn.
- Completed
- Registry status
- NA
- Development phase
NCT00002094: Completed NA study, sponsored by Pharmacia and Upjohn.
NCT00002094 is a NA study that has completed, run by Pharmacia and Upjohn. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002094, a NA study, has completed, sponsored by Pharmacia and Upjohn.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To determine the time course of development of resistance to atevirdine mesylate ( U-87201E ) in patients with HIV isolates showing in vitro resistance to zidovudine ( AZT ). To determine the genotype changes in HIV reverse transcriptase associated with in vitro AZT resistance to U-87201E. To determine the genotype and phenotype effects of treatment with a nondideoxynucleoside agent on the alterations of the HIV-1 population associated with in vitro AZT resistance. To determine whether serial passage of patient pre-drug HIV isolates in the presence of U-87201E will generate the resistant mutants that may subsequently emerge in the patients.
Interventions
- DRUG Atevirdine mesylate
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002094 record still lists
NCT00002094 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Atevirdine mesylate is the first listed.
NCT00002094 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002094 about?
NCT00002094 is a clinical study titled "Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E". To determine the time course of development of resistance to atevirdine mesylate ( U-87201E ) in patients with HIV isolates showing in vitro resistance to zidovudine ( AZT ). To determine the genotype changes in HIV reverse transcriptase associated with in vitro AZT resistance to U-87201E. To determ...
What is the current status of trial NCT00002094?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002094?
The interventions under investigation include: Atevirdine mesylate (DRUG).
Who is sponsoring clinical trial NCT00002094?
This trial is sponsored by Pharmacia and Upjohn, which has 11 total clinical trials registered on ClinicalTrials.gov.